StockNews.com assumed coverage on shares of 22nd Century Group (NASDAQ:XXII – Free Report) in a report released on Sunday. The brokerage issued a sell rating on the biotechnology company’s stock.
22nd Century Group Stock Up 5.1 %
Shares of XXII stock opened at $0.12 on Friday. 22nd Century Group has a 12 month low of $0.09 and a 12 month high of $8.63. The company has a market cap of $1.01 million, a PE ratio of 0.00 and a beta of 1.39. The business’s 50 day moving average is $0.28 and its two-hundred day moving average is $0.80.
22nd Century Group (NASDAQ:XXII – Get Free Report) last posted its earnings results on Tuesday, August 13th. The biotechnology company reported ($0.36) earnings per share (EPS) for the quarter. The firm had revenue of $7.95 million during the quarter. 22nd Century Group had a negative net margin of 275.12% and a negative return on equity of 380.39%.
Institutional Investors Weigh In On 22nd Century Group
22nd Century Group Company Profile
22nd Century Group, Inc, a tobacco products company, engages in the sale and distribution of its own proprietary new reduced nicotine tobacco products. The company offers reduced nicotine content tobacco plants and very low nicotine combustible cigarette products. It also provides contract manufacturing services for conventional combustible tobacco products for third-party brands.
See Also
- Five stocks we like better than 22nd Century Group
- Transportation Stocks Investing
- Chinese Stocks Cool Off: Time to Buy the Dip in These 2 Stocks?
- Basic Materials Stocks Investing
- Goldman Sachs Highlights 3 Top Short Squeeze Stocks to Watch
- How to Start Investing in Real Estate
- Walmart is Up 56% YTD, Is it Still a Top Consumer Staples Stock?
Receive News & Ratings for 22nd Century Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for 22nd Century Group and related companies with MarketBeat.com's FREE daily email newsletter.